METTL1 and cancer: Future prospects should thus focus on addressing these gaps through advancing cancer genomics with technologies like CRISPR and RNA sequencing to uncover METTL1’s full role across diverse cancer subtypes, facilitating better patient stratification, while collaborative efforts between basic scientists and clinicians are essential to accelerate discoveries in METTL1-targeted strategies and promote clinical translation, thereby fostering innovations that improve patient outcomes despite existing complexities.